— Plus: bardoxolone methyl for diabetic kidney disease and spironolactone in hemodialysis patients
By Kristen Monaco
PHILADELPHIA — Some of the latest research in the field of nephrology presented at the American Society of Nephrology’s Kidney Week included sparsentan in focal segmental glomerulosclerosis, combination treatment with an SGLT2 inhibitor and an endothelin A receptor antagonist, and a novel aldosterone synthase inhibit in chronic kidney disease. Below are a few more highlights.
Read the full story in MedPage Today.